APP, amyloid beta precursor protein, 351

N. diseases: 485; N. variants: 114
Disease: Memory impairment ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Our data demonstrated that xanthoceraside may promote the proliferation and differentiation of NSCs into neurons by up-regulating the Wnt/β-catenin pathway to fill the neuronal loss, thereby improving learning and memory impairment in APP/PS1 transgenic mice. 28744803 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE BBR improved learning and memory deficits of APP/PS1 mice. 29962345 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE We found that SY treatment significantly ameliorated the learning and memory deficits of APP/PS1 mice. 29288971 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE The Morris water maze and Y-maze test results showed that eight weeks of intragastric administration of LIG (10 mg/kg, 40 mg/kg) every day improved memory deficit in APP/PS1 mice. 30079347 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 AlteredExpression phenotype BEFREE We found that oral treatment with FLDK reversed learning and memory impairment, reduced Aβ burden and expression of β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and decreased microglial activation in senile plaques. 29038004 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE DMDD has potential benefit on treating learning and memory deficit in APP/PS1 transgenic AD mice, and its effects may be associated with reversing the apoptosis of neuron via inhibiting Bax/Bcl-2 mediated mitochondrial membrane potential loss. 30196278 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Human studies and mouse models of Alzheimer's disease suggest that the amyloid precursor protein (APP) can cause changes in synaptic plasticity and is contributing to the memory deficits seen in Alzheimer's disease. 28168961 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Depletion of endogenous tau in an amyloid precursor protein (APP) transgenic (J20) mouse line was shown to ameliorate hippocampal hyperactivity in J20 animals, tau depletion failed to reverse memory deficits associated with APP/Aβ overproduction. 29545742 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE In conclusion, our data show that HDAC3 inhibition can attenuate spatial memory deficits and inhibit oxidative stress in APP/PS1 mice; these results indicate a potential strategy for AD treatment. 29376873 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Hesperidin attenuates learning and memory deficits in APP/PS1 mice through activation of Akt/Nrf2 signaling and inhibition of RAGE/NF-κB signaling. 26391026 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE The memory impairment associated to APP/PS1 transgene was accelerated in these mice. 30096288 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE LiCl treatment restored the long-term spatial memory deficit observed in APP/PS1 mice as assessed by the water maze (back to similar levels of escape latency as WT mice), but the short-term memory deficit remained unaffected by LiCl treatment. 29545118 2018
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects. 28065587 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Second, we used an APPswe/PS1E9 (APP/PS1) double transgenic mice to evaluate the amelioration ability of simvastatin against the memory impairment in vivo. 28528185 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE SEN1500, an orally bioavailable and CNS-penetrant Aβ aggregation inhibitor, has previously been shown to reduce spatial learning and memory deficits in an APP transgenic mouse model. 28917978 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF-β/Smad2/STAT3 signaling. 28366226 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Here we identified that overexpression of EphB2 with lentiviral vectors in dorsal hippocampus improved impaired memory deficits and anxiety or depression-like behaviors in APPswe/PS1-dE9 (APP/PS1) transgenic mice. 28358367 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE We reported that DcR3 ameliorates hippocampus-dependent memory deficits and reduces amyloid plaque deposition in APP transgenic mouse. 28438208 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 AlteredExpression phenotype BEFREE The open field test, Morris water maze test, and fear condition test revealed that PSD-93 overexpression ameliorated spatial memory deficits in APP/PS1 mice. 28697571 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE The study provides preclinical evidence that Fasudil treatment ameliorated memory deficits in APP/PS1 Tg mice, accompanied by the reduction of Aβ deposition and Tau protein phosphorylation, the decrease of BACE and the increase of PSD-95, as well as inhibition of TLRs-NF-κB-MyD88 inflammatory cytokine axis. 27401064 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype CTD_human Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease. 28448946 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE APP/PS1 mice exhibited significant memory deficits from 5 months old, which were aggravated at the later stage of life. 28191738 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE We found that hAM-MSC transplantation into the hippocampus dramatically reduced amyloid-β peptide (Aβ) deposition and rescued spatial learning and memory deficits in APP/PS1 mice. 28397068 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice. 28743230 2017
CUI: C0233794
Disease: Memory impairment
Memory impairment 		0.500 Biomarker phenotype BEFREE Antioxidative and Anti-Apoptotic Roles of Silibinin in Reversing Learning and Memory Deficits in APP/PS1 Mice. 28852940 2017